Integrin Alpha6 Detection and Inhibition for Leptomeningeal Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leptomeningeal disease (LMD) are ineffective, and there is a lack of targeted molecular therapies due to a poor understanding of the molecular mechanisms governing LMD.
Innovation Solution
The development of methods for detecting and predicting LMD by identifying the presence of integrin α6 and breast cancer cells expressing integrin α6, along with the use of agents to inhibit the expression and activity of integrin α6, breast cancer cells expressing integrin α6, glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy, radiation, and corticosteroids are used to treat LMD, then treatment coverage is provided, but treatment effectiveness is poor and patients succumb within weeks to months
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific chemotherapy/radiation to targeted inhibition of integrin α6 and GDNF pathways. This molecular-level parameter change enables selective intervention in LMD pathogenesis, improving treatment effectiveness while reducing harm to normal tissues.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediary substances that specifically block integrin α6 and GDNF interactions. These intermediaries mediate the therapeutic effect by preventing the molecular mechanisms driving LMD progression, thereby extending patient survival.
2Measurement precision
If targeted molecular therapies are developed, then treatment precision is improved, but the paucity of such therapies exists due to poor understanding of molecular mechanisms
Solution Approach 1:
The patent performs preliminary detection of integrin α6 and GDNF expression levels before initiating targeted therapy. This preliminary action identifies patients who will benefit from integrin/GDNF inhibition, enabling precise patient selection and improving treatment outcomes while simplifying the clinical implementation complexity.
3Reliability
If integrin α6 and GDNF pathways are targeted, then LMD progression is inhibited, but the complexity of identifying and administering targeted agents increases
Solution Approach 1:
The patent employs small molecule inhibitors that can target multiple components of the integrin/GDNF pathway simultaneously. This multi-functionality simplifies the therapeutic regimen by using a single agent to block multiple pro-survival signals, reducing the complexity of administering multiple targeted therapies.
Data Source
AI summary
This disclosure provides compositions and methods for detecting, methods for predicting a risk of developing, and methods for treating systemic and brain parenchymal metastases including leptomeningeal disease (LMD). In particular, provided herein are methods for detecting and/or predicting a risk of developing systemic and brain parenchymal metastases including LMD in a subject (e.g., a human subject) through identifying the presence or absence of integrin a6 and/or breast cancer cells (BCCs) expressing integrin a6 in a sample obtained from the subject. In addition, provided herein are methods for treating, ameliorating, or preventing systemic and brain parenchymal metastases including LMD in a subject through inhibiting expression and/or activity of one or more of integrin a6, BCCs expressing integrin a6, neuroprotective factor glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM).